Jason Foss

Managing Director, Americas
Healthcare

Jason Foss is a Managing Director with Results Healthcare based in Atlanta, GA. He has over 20 years of corporate finance advisory experience, most of which have been focussed on the pharmaceutical sector. He is deeply experienced in advising companies on mergers and acquisitions and capital raising projects, having advised on transactions valued at nearly $25bn during his career.

He began his career with Morgan Stanley in New York in their healthcare investment banking group in 1995. He relocated to London in 1999, and worked with UBS and Citi in similar roles, during which times he worked on such significant transactions as the IPO of Hikma Pharmaceuticals and Roche’s acquisition of Ventana Medical Systems.

In 2014, Jason returned home to lead Results Healthcare’s Life Sciences efforts in the US. Since then he has worked on a variety of interesting M&A and capital raising transactions, for clients such as GSK, Sanofi, UCB, and Merck, among others.

Jason has a Masters in Business Administration (MBA) from the University of Chicago’s Booth School of Business and a BA in Psychology from Georgetown University. He speaks Russian and is an avid golfer.

Latest Insights

Insights
7th August 2020

A view from America: Living in the age of COVID-19 and where things go from here

To say that America has struggled to cope with the COVID-19 pandemic is something of an understatement. With well over 3 million infections and 130 thousand deaths – and the numbers continuing to rise – we’re unfortunately at the top of the league tables in terms of countries affected by the pandemic. Explanations for the […]

Insights
9th July 2020

Deal activity and valuations in the healthcare sector during COVID-19

There has been a measurable impact on healthcare deal activity and valuations as a result of COVID-19. Major equity indices experienced a remarkable dip following the COVID-19 outbreak but appear to have stabilised and recovered the lost ground. Debt market spreads, especially sub-investment grade, spiked in March but have been gradually reducing as lockdown is […]